Cytomid tablets 250mg are used to treat prostate cancer which is in an advanced stage, and is a palliative treatment for advanced prostatic cancer in previously untreated patients or those who have not responded, stopped responding (become refractory) or cannot tolerate other hormonal treatments. Cytomid 250 is generally used in combination with another medication, a luteinizing hormone-releasing hormone (LHRH) agonist that induces medical castration, which means that testosterone is no longer produced by the testes and this helps in the treatment of prostate cancer. Alternatively, Cytomid 250 is used in combination with surgical castration. Cytomid tablets 250mg may also be used to prevent a flare reaction associated with the initial use of LHRH agonist therapy, which is when large amounts of testosterone are suddenly produced in response to LHRH, before testosterone production is switched off, and may be painful or harmful in advanced prostate cancer, which has become metastatic (spread to other sites outside the prostate).
How does Cytomid work?
Cytomid tablets 250mg contain flutamide, a non-steroidal anti-androgen, which acts as a testosterone analogue as it is similar in structure to testosterone and binds to the same receptor in prostate cells but without activating any normal testosterone actions. Prostate cancer is a testosterone-dependent tumour, which means that it needs testosterone to grow. Testosterone is an androgen or male hormone that is produced in the testes and is responsible for the secondary sexual characteristics, such as facial hair and increased muscle mass; it is also required for the prostate gland to function normally. Flutamide in Cytomid 250 binds to the androgen receptor in prostate cancer cells, which blocks the stimulation by testosterone of cancer cell growth and helps slow or prevent progression of the tumour.
What does Cytomid contain?
Cytomid tablets 250mg contain the active ingredient flutamide, a non-steroidal
anti-androgen, which acts as a testosterone analogue to treat prostate cancer.
